文献速递泌尿生殖与妇科肿瘤放疗

治疗前血浆骨桥蛋白水平作为前列腺癌根治性放疗联合激素治疗反应标志物的研究

Pretreatment plasma osteopontin level as a marker of response to curative radiotherapy and hormonal treatment for prostate cancer.
PubMed 文献 · Radiother Oncol · 2024-08-31

研究纳入2012至2014年274例接受放疗的前列腺癌患者,按血浆骨桥蛋白(OPN)中位浓度83.9 ng/mL分为A组(低于中位)和B组(高于中位)。OPN与Gleason评分、D'Amico风险、ADT及RT分组间差异显著,与临床分期正相关;OPN对bRFS、RFS、MFS无显著影响,但A组10年OS率81% vs B组60%(p<0.001)。Cox分析显示低OPN水平与更高OS相关,OPN对生存的预后影响随ADT持续时间延长而减弱。

要点

  • A组10年OS率81% vs B组60%(p<0.001),低OPN组生存更优。
  • OPN与Gleason评分(p=0.005)、D'Amico风险(p=0.002)、ADT(p<0.001)及RT(p=0.019)分组间差异显著。
  • OPN对bRFS、RFS和MFS无显著影响,但与临床分期正相关(p=0.042)。

核心结论

  • 基于所得结果,作者假设放疗开始前测定的OPN水平可能是接受放疗联合或不联合ADT的前列腺癌患者OS的独立预测因子。

研究设计与样本

  • 2012年至2014年间纳入274例符合放疗条件的前列腺癌患者,其中34.3%接受SCADT、46.3%接受LCADT。
  • 按血浆OPN中位浓度83.9 ng/mL将患者分为A组(低于中位)和B组(高于中位)进行分析。

主要发现

  • OPN在Gleason评分(p=0.005)、D'Amico风险(p=0.002)、ADT(p<0.001)和RT(p=0.019)分组间差异显著。
  • OPN与临床分期呈正相关(p=0.042)。
  • OPN对bRFS、RFS和MFS无显著影响。
  • A组10年OS率为81%,B组为60%(p<0.001)。
  • Cox分析显示低OPN水平(p<0.001)、低年龄(p=0.002)和低Gleason评分(p=0.038)与更高OS相关;OPN对生存的预后影响随ADT持续时间延长而减弱,单纯RT时OPN效应最强(HR=3.93),SCADT时较弱(HR=2.48),LCADT时最弱(HR=2.09)。

关键数值与推荐

  • 血浆OPN中位浓度为83.9 ng/mL,以此界值定义A组(低于中位)和B组(高于中位)。
  • 单纯RT时OPN的HR=3.93,SCADT时HR=2.48,LCADT时HR=2.09。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Osteopontin is a known marker for tumour hypoxia with relevance for the outcome of radiotherapy. We analysed the plasma concentration of OPN in prostate cancer patients receiving RT with or without ADT to evaluate OPN as a potential marker of treatment response. MATERIALS AND METHODS: Between 2012 and 2014, 274 patients with prostate cancer qualifying for RT were enrolled to the study. SCADT received 34.3 % of patients, LCADT 46.3 %. The median OPN concentration was 83.9 ng/mL. We analysed the groups by OPN level: group A with OPN below and group B with OPN above the median. RESULTS: There was a significant difference in OPN between the Gleason score (p = 0.005), the D'Amico risk (p = 0.002), the ADT (p < 0.001) and the RT (p = 0.019) groups. We found a positive correlation between OPN and clinical stage (p = 0.042). There were no significant effect of OPN on bRFS, RFS and MFS. The 10-year OS rate for group A was 81 % and for group B 60 % (p < 0.001). Cox analysis showed that low OPN level (p < 0.001), low age (p = 0.002) and low Gleason score (p = 0.038) were associated with higher OS. The prognostic influence of OPN on survival decreased with duration of ADT with the strongest effect of OPN (HR=3.93) observed when RT alone was used, weakest effect (HR=2.48) for SCADT and the smallest effect (HR=2.09) for LCADT. CONCLUSIONS: Based on the obtained results, we assume that the level of OPN measured before the start of radiotherapy may be an independent predictor of OS of patients with prostate cancer treated with radiotherapy with and without ADT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Smolska-Ciszewska B, Mrochem-Kwarciak J, Karczmarczyk K, et al. Pretreatment plasma osteopontin level as a marker of response to curative radiotherapy and hormonal treatment for prostate cancer. Radiother Oncol. 2024. PMID: 39222849. doi:10.1016/j.radonc.2024.110518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。